Compositions comprising dimethyl sulfoxide (DMSO)

• US 9,427,419 B2
• Filed: 09/11/2006
• Issued: 08/30/2016
• Est. Priority Date: 09/12/2005
• Status: Active Grant

• Current Assignee: Abela Pharmaceuticals, Inc.
• Original Assignee: Abela Pharmaceuticals, Inc.
• Inventors: De La Torre, Jack
• Primary Examiner(s): West, Theodore R
• Application Number:
  US12/066,487
• Publication Number:
  US 20090312273A1
• Time in Patent Office: 3,641 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/10 Sulfides; Sulfoxides; Sulfones
• CPC Class Codes: A61K 31/17 having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates generally to compositions comprising dimethylsulfoxide (DMSO) and associated compounds in combination with one or more of the following: fructose 1,6-diphosphate, L-arginine, L-lysine, L-aspartate, and urea. Methods for treating traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses are also provided.

Claims

1. A method of treating brain injury, the method consisting essentially of:

administering a composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine and one or more pharmaceutically-acceptable carriers to a brain injury patient,

wherein the DMSO is present in a concentration range of about 20% to about 40% in the composition,

wherein the L-arginine is present in a range of about 0.5% to about 10% weight per volume of the composition,

wherein the administering is intravenous, and

wherein the brain injury is a spinal cord injury or a traumatic brain injury.

2. The method of claim 1, further comprising preparing the composition prior to the administering, wherein the preparing comprises combining at least the DMSO and the L-arginine.

3. The method of claim 1, wherein the DMSO is present in the composition in has a concentration in a range of about 20% to about 30%.

4. The method of claim 1, wherein the DMSO is present in in the composition in a concentration of about 28%.

5. The method of claim 1, wherein the pharmaceutically-acceptable carrier is saline.

6. A method of treating a patient with brain injury, said method comprising:

obtaining a composition comprising dimethylsulfide (DMS) and L-arginine in a therapeutically effective dose,

wherein said therapeutically effectively dose of DMS is a concentration of about 20% to 40% of said composition and said therapeutically effective dose of L-arginine is about 0.5% to about 10% weight per volume of said composition; and

administering said composition intravenously to said patient, wherein said brain injury is a spinal cord injury or a traumatic brain injury.

7. The method of claim 6, further comprising administering at least one of methylsulfonylmethane (MSM), urea, and dimethylsuloxide (DMSO).

8. The method of claim 7, wherein the administering at least one of methylsulfonylmethane (MSM), urea, and dimethylsulfoxide (DMSO) comprises administering orally.

9. The method of claim 6, wherein the dimethylsulfide (DMS) is present in said composition in a concentration of about 28%.

10. The method of claim 6, wherein said composition further comprises a compound selected from the group consisting of one or more of the following:

L-lysine and L-aspartine.

11. The method of claim 6, wherein said composition further comprises urea in a concentration in a range of about 20% to about 60%.

12. The method of claim 11, wherein at least one of said DMSO, said L-arginine, and said urea is administered intravenously at a rate of about 10 ml/min.

13. A method of increasing blood flow in the central nervous system, consisting essentially of:

intravenously administering a therapeutically effective dose of a pharmaceutical composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine, and one or more pharmaceutically-acceptable carriers to a subject having a spinal cord injury or a traumatic brain injury.

14. A method of treating brain injury, consisting essentially of:

administering a therapeutically effective dose of a pharmaceutical composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine, urea, and one or more pharmaceutically-acceptable carriers

to an individual having a brain injury, wherein said brain injury comprises a spinal cord injury or a traumatic brain injury.

15. A method of treating brain injury, the method consisting essentially of:

administering a composition consisting essentially of DMSO, L-arginine and one or more pharmaceutically-acceptable carriers to a brain injury patient,

wherein said DMSO is present in a concentration range of about 20% to about 40% in the first composition,

wherein said L-arginine is present in a range of about 0.5% to about 10% weight per volume of said first composition,

wherein said brain injury is a spinal cord injury or a traumatic brain injury.

16. A method of treating brain injury, consisting essentially of:

administering a therapeutically effective dose of a pharmaceutical composition consisting essentially of dimethylsulfoxide (DMSO), L-arginine, MSM, and one or more pharmaceutically-acceptable carriers

to an individual having a brain injury, wherein said brain injury comprises a spinal cord injury or a traumatic brain injury.

17. A method of treating brain injury, comprising:

administering a therapeutically effective dose of a composition comprising dimethylsulfide (DMS), L-arginine, MSM, and one or more pharmaceutically-acceptable carriers to an individual having a brain injury, wherein said brain in jury comprises a spinal cord injury or a traumatic brain injury.

18. A method of treating brain injury, comprising:

administering a therapeutically effective dose of a pharmaceutical composition comprising dimethylsulfide (DMS), L-arginine, urea, and one or more pharmaceutically-acceptable carriers to an individual having a brain injury, wherein said brain injury comprises a spinal cord injury or a traumatic brain injury.

19. A method, comprising:

administering a composition to a patient, the composition consisting essentially of;

dimethylsulfoxide (DMSO),

at least one of L-arginine, L-lysine, L-aspartate, dimethylsulfide (DMS), methylsulfonylmethane (MSM), and urea, and

one or more pharmaceutically-acceptable carriers.

20. The method of claim 19, wherein the patient is a brain injury patient.

21. The method of claim 20, wherein the brain injury is a spinal cord injury or a traumatic brain injury.

22. A method, comprising:

administering a composition to a patient, the composition comprising;

dimethylsulfide (DMS),

at least one of L-arginine, L-lysine, L-aspartate, dimethylsulfoxide (DMSO), methylsulfonylmethane (MSM), and urea, and

one or more pharmaceutically-acceptable carriers.

23. The method of claim 22, wherein the patient is a brain injury patient.

24. The method of claim 23, wherein the brain injury is a spinal cord injury or a traumatic brain injury.